Fiche personne
Territoire
Alsace
Statut
Hospitalier
Équipes/plateformes
Publications
Anastomotic biliary stricture after orthotopic liver transplantation: what can we propose after failure of classic ERCP technique to cannulate the stricture?
Mayer P, Christmann PY, Héroin L, Habersetzer F
Endoscopy. 2024 12;56(S 01):E150-E152
Black esophagus: complete esophageal necrosis with lower esophageal perforation.
Héroin L, Christmann PY, Habersetzer F, Mayer P
Endoscopy. 2024 12;56(S 01):E53-E54
Complete section of the common bile duct during complicated cholecystectomy: laparoscopy-guided endoscopic treatment, a mini-invasive approach.
Mayer P, Héroin L, Philouze G, Habersetzer F, Pessaux P, Badaoui A, Lapergola A
Endoscopy. 2024 12;56(S 01):E1003-E1005
Rescue endoscopic treatment with completion by radical surgery following misplacement of a partially covered metal stent in an anastomotic fistula post-Lewis Santy esophagectomy.
Mayer P, Héroin L, Habersetzer F, Christmann PY, Huppertz J, Sosa-Valencia L, Badaoui A
Endoscopy. 2024 12;56(S 01):E716-E717
Single-cell RNA-sequencing of virus-specific cellular immune responses in chronic hepatitis B patients.
Hatje K, Kam-Thong T, Giroud N, Saviano A, Simo-Noumbissie P, Kumpesa N, Nilsson T, Habersetzer F, Baumert TF, Pelletier N, Forkel M
Sci Data. 2024 04 8;11(1):355
Impact of anti-HDV reflex testing at HBs antigen positive discovery in a single center France: Support for primary HDV screening in France.
Parfut A, Tripon S, Gantner P, Chaffraix F, Laugel E, Wendling MJ, Erol F, Wiedemer C, Doffoel M, Saviano A, Royant M, Habersetzer F, Fafi-Kremer S, Velay A
J Clin Virol. 2024 02 3;171:105650
Left-sided portal hypertension: Update and proposition of management algorithm.
Mayer P, Venkatasamy A, Baumert TF, Habersetzer F, Pessaux P, Saviano A, Felli E
J Visc Surg. 2023 12 22;:
Abdominal pain in a young man revealing an infected perigastric cystic lymphangioma.
Mayer P, Felli E, Pessaux P, Huppertz J, Habersetzer F, Héroin L, Philouze G
Endoscopy. 2023 12;55(S 01):E727-E728
An unusual complication of acute biliary pancreatitis: an incidental discovery of hemobilia.
Mayer P, Wackenthaler A, Christmann PY, Habersetzer F, de Marini P, Héroin L
Endoscopy. 2023 12;55(S 01):E631-E632
Chronic ischemic ileitis after ileocecal resection and ileocolic anastomosis.
Vuola S, Héroin L, Habersetzer F, Philouze G, Mayer P
Endoscopy. 2023 12;55(S 01):E729-E730
Post-cholecystectomy biliary leakage mimicking a neoplastic lesion: contribution of cholangioscopy in diagnosis and endoscopic treatment.
Mayer P, Christmann PY, Venkatasamy A, Uhl G, Vuola S, Heroin L, Habersetzer F
Endosc Int Open. 2023 09;11(9):E885-E887
Risk factors for endoscopic ultrasound-guided radiofrequency ablation adverse events in patients with pancreatic neoplasms: a large national French study (RAFPAN study).
Napoléon B, Lisotti A, Caillol F, Gasmi M, Ah-Soune P, Belle A, Charachon A, Cholet F, Eyraud PY, Grandval P, Gonzalez JM, Habersetzer F, Koch S, Le Rhun M, Mangialavori L, Musquer N, Palazzo M, Poincloux L, Privat J, Sportes A, Stouvenot M, Subtil C, Thomassin L, Vanbiervliet G, Vidal G, Vuitton L, Giovannini M, Barthet M
Gastrointest Endosc. 2023 04 12;:
An impossible biliary drainage? Fistulization of a degenerated intraductal papillary mucinous pancreatic neoplasm to the common bile duct.
Mayer P, Héroin L, Sosa-Valencia L, Dautrecque F, Pessaux P, Saviano A, Habersetzer F
Endoscopy. 2022 09 22;:
An unusual malignant main bile duct stricture: a biliary metastasis of endometrial adenocarcinoma.
Mayer P, Héroin L, Averous G, Pioche M, Lepeut G, Felli E, Habersetzer F
Endoscopy. 2022 08 4;:
Changes in the profile and therapeutic care of people who use drugs with HCV mono-infection: a retrospective study between 2015 and 2019 from a monocentric tertiary referent center in France.
Doffoel M, Tripon S, Ernwein F, Chaffraix F, Haumesser L, Bader R, Lang JP, Lang A, Paya D, Royant M, Velay-Rusch A, Tebacher M, Meyer N, Habersetzer F, Baumert T
Eur J Gastroenterol Hepatol. 2022 May 1;34(5):560-566
Safety and antiviral activity of EGFR inhibition by erlotinib in chronic hepatitis C patients: a phase Ib randomized controlled trial.
Saviano A, Habersetzer F, Lupberger J, Simo-Noumbissie P, Schuster C, Doffoël M, Schmidt-Mutter C, Baumert TF
Clin Transl Gastroenterol. 2022 Apr 1;:
Combined endoscopic and surgical management of a right intrahepatic bile duct injury during laparoscopic cholecystectomy.
Mayer P, Héroin L, Habersetzer F, Vix M, Pessaux P, Felli E, Mathis G
Endoscopy. 2022 Feb 18;:
Perforation of the greater gastric curvature by a gastric adenocarcinoma with engulfment of the upper pole of the spleen.
Mayer P, Héroin L, Mutter D, Oertel L, Pioche M, Habersetzer F, Philouze G
Endoscopy. 2022 Feb 18;:
Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis.
Pageaux GP, Nzinga CL, Ganne N, Samuel D, Dorival C, Zoulim F, Cagnot C, Decaens T, Thabut D, Asselah T, Mathurin P, Habersetzer F, Bronowicki JP, Guyader D, Rosa I, Leroy V, Chazouilleres O, de Ledinghen V, Bourliere M, Causse X, Cales P, Metivier S, Loustaud-Ratti V, Riachi G, Alric L, Gelu-Simeon M, Minello A, Gournay J, Geist C, Tran A, Abergel A, Portal I, d'Alteroche L, Raffi F, Fontaine H, Carrat F, Pol S,
BMC Infect Dis. 2022 Jan 27;22(1):94
Characteristics and care of chronic hepatitis C treated with direct-acting antivirals in migrants.
Doffoel M, Ernwein F, Chaffraix F, Haumesser L, Tripon S, Bader R, Lang JP, Lang A, Paya D, Royant M, Velay-Rusch A, Tebacher M, Meyer N, Habersetzer F, Baumert T
Eur J Gastroenterol Hepatol. 2021 Dec 30;:
Upper gastrointestinal bleeding due to left side portal hypertension after pancreatic surgery.
Mayer P, Felli E, Enescu I, Habersetzer F, Tripon S
Hepatobiliary Pancreat Dis Int. 2021 Dec 30;:
Differences between sporadic hyperplastic gastric polyps and portal hypertensive gastric polyps: a review.
Héroin L, Saviano A, Fenouil T, Sosa-Valencia L, Baumert TF, Habersetzer F, Mayer P
Eur J Gastroenterol Hepatol. 2021 Aug 23;:
Predictive Factors for Hepatocellular Carcinoma in Chronic Hepatitis B Using Structural Equation Modeling: A Prospective Cohort Study.
Lam L, Fontaine H, Bourliere M, Lusivika-Nzinga C, Dorival C, Thabut D, Zoulim F, Habersetzer F, Asselah T, Duclos-Vallee JC, Bronowicki JP, Mathurin P, Decaens T, Ganne N, Guyader D, Leroy V, Rosa I, Ledinghen V, Cales P, Causse X, Larrey D, Chazouilleres O, Gelu-Simeon M, Loustaud-Ratti V, Metivier S, Alric L, Riachi G, Gournay J, Minello A, Tran A, Geist C, Abergel A, Raffi F, D'alteroche L, Portal I, Lapidus N, Pol S, Carrat F,
Clin Res Hepatol Gastroenterol. 2021 Apr 27;:101713
Safe administration of corticosteroids in severe ulcerative colitis and active SARS-CoV2 infection.
Mayer P, Saviano A, Kassegne L, Baumert TF, Reimund JM, Habersetzer F
Dig Liver Dis. 2020 Jul 27;:
Intraabdominal urokinase in the treatment of loculated infected ascites in cirrhosis.
Tripon S, Mayer P, Svab A, Habersetzer F, Pessaux P, Baumert TF, Enescu I
Clin Res Hepatol Gastroenterol. 2020 Jul 9;:
Sustained Remission After Treatment Withdrawal in Autoimmune Hepatitis: A Multicenter Retrospective Study.
Ben Merabet Y, Barbe C, Heurgue-Berlot A, Thévenot T, Minello A, Habersetzer F, Samuel D, Bernard-Chabert B, Weil-Verhoeven D, Renard P, Clot H, Di Martino V, Louvet H, Bresson-Hadni S, Thiéfin G
Dig. Dis. Sci.. 2020 Jun 30;:
Safety and Immunogenicity of the Therapeutic Vaccine TG1050 in Chronic Hepatitis B Patients: A Phase 1b Placebo-Controlled Trial.
Zoulim F, Fournier C, Habersetzer F, Sprinzl M, Pol S, Coffin CS, Leroy V, Ma M, Wedemeyer H, Lohse AW, Thimme R, Lugardon K, Martin P, Bastien B, Sansas B, Adda N, Halluard C, Bendjama K, Brandely M, Inchauspé G
Hum Vaccin Immunother. 2019 Aug 2;:
IFITMs mediate viral evasion in acute and chronic hepatitis C virus infection.
Wrensch F, Ligat G, Heydmann L, Schuster C, Zeisel MB, Pessaux P, Habersetzer F, King BJ, Tarr AW, Ball JK, Winkler M, Pöhlmann S, Keck ZY, Foung SKH, Baumert TF
Hepatology. 2019 May 7;:
Hepatitis B virus reactivation in transplant patients treated for hepatitis C recurrence: Prophylaxis makes the difference.
Mouna L, Rossignol E, Tateo M, Coilly A, Duclos-Vallée JC, Duvoux C, Durand F, Tran A, Radenne S, Canva-Delcambre V, Houssel-Debry P, Dumortier J, Conti F, de Ledinghen V, Leroy V, Kamar N, Di Martino V, Moreno C, Botta Fridlund D, d'Alteroche L, Lebray P, Perre P, Besch C, Silvain C, Habersetzer F, Debette-Gratien M, Abergel A, Diallo A, Samuel D, Roque-Afonso AM, Pageaux GP,
J. Hepatol.. 2019 Apr 6;:
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial.
Merle P, Blanc JF, Phelip JM, Pelletier G, Bronowicki JP, Touchefeu Y, Pageaux G, Gerolami R, Habersetzer F, Nguyen-Khac E, Casadei-Gardini A, Borbath I, Tran A, Wege H, Saad AS, Colombo M, Abergel A, Richou C, Waked I, Yee NS, Molé A, Attali P, Le Boulicaut J, Vasseur B,
Lancet Gastroenterol Hepatol. 2019 Apr 3;:
HCV-induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response.
Hamdane N, Jühling F, Crouchet E, El Saghire H, Thumann C, Oudot MA, Bandiera S, Saviano A, Ponsolles C, Roca Suarez AA, Li S, Fujiwara N, Ono A, Davidson I, Bardeesy N, Schmidl C, Bock C, Schuster C, Lupberger J, Habersetzer F, Doffoël M, Piardi T, Sommacale D, Imamura M, Uchida T, Ohdan H, Aikata H, Chayama K, Boldanova T, Pessaux P, Fuchs BC, Hoshida Y, Zeisel MB, Duong FHT, Baumert TF
Gastroenterology. 2019 Mar 2;:
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, De Ledinghen V, Larrey D, Haour G, Bronowicki JP, Zoulim F, Asselah T, Marcellin P, Thabut D, Leroy V, Tran A, Habersetzer F, Samuel D, Guyader D, Chazouilleres O, Mathurin P, Metivier S, Alric L, Riachi G, Gournay J, Abergel A, Cales P, Ganne N, Loustaud-Ratti V, D'Alteroche L, Causse X, Geist C, Minello A, Rosa I, Gelu-Simeon M, Portal I, Raffi F, Bourliere M, Pol S,
Lancet. 2019 Feb 11;:
Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE).
Moehler M, Heo J, Lee HC, Tak WY, Chao Y, Paik SW, Yim HJ, Byun KS, Baron A, Ungerechts G, Jonker D, Ruo L, Cho M, Kaubisch A, Wege H, Merle P, Ebert O, Habersetzer F, Blanc JF, Rosmorduc O, Lencioni R, Patt R, Leen AM, Foerster F, Homerin M, Stojkowitz N, Lusky M, Limacher JM, Hennequi M, Gaspar N, McFadden B, De Silva N, Shen D, Pelusio A, Kirn DH, Breitbach CJ, Burke JM
Oncoimmunology. 2019 ;8(8):1615817
Impact of Cytomegalovirus Infection on the Outcome of Patients With Cirrhosis: A Preliminary Study.
Faivre M, Cottet V, Bour JB, Richou C, Valmary-Degano S, Thiefin G, Andreoletti L, Geist C, Schvoerer E, Malvé B, Habersetzer F, Fafi-Kremer S, Binquet C, Jouve JL, Bronowicki JP, Doffoel M, Hillon P, Herbein G, Monnet E, Di Martino V,
J. Clin. Gastroenterol.. 2018 Oct 31;:
Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection.
Seto WK, Asahina Y, Brown TT, Peng CY, Stanciu C, Abdurakhmanov D, Tabak F, Nguyen TT, Chuang WL, Inokuma T, Ikeda F, Santantonio TA, Habersetzer F, Ramji A, Lau AH, Suri V, Flaherty JF, Wang H, Gaggar A, Subramanian GM, Mukewar S, Brunetto MR, Fung S, Chan HL
Clin. Gastroenterol. Hepatol.. 2018 Jun 19;:
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.
Corpechot C, Chazouillères O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, Goria O, Potier P, Minello A, Silvain C, Abergel A, Debette-Gratien M, Larrey D, Roux O, Bronowicki JP, Boursier J, de Ledinghen V, Heurgue-Berlot A, Nguyen-Khac E, Zoulim F, Ollivier-Hourmand I, Zarski JP, Nkontchou G, Lemoinne S, Humbert L, Rainteau D, Lefèvre G, de Chaisemartin L, Chollet-Martin S, Gaouar F, Admane FH, Simon T, Poupon R
N. Engl. J. Med.. 2018 06 7;378(23):2171-2181
Safety of sofosbuvir-based regimens after liver transplantation: longitudinal assessment of renal function in the prospective ANRS CO23 CUPILT study.
Anty R, Favre G, Coilly A, Rossignol E, Houssel-Debry P, Duvoux C, De Ledinghen V, Di Martino V, Leroy V, Radenne S, Kamar N, Canva V, D'Alteroche L, Durand F, Dumortier J, Lebray P, Besch C, Tran A, Canivet CM, Botta-Fridlund D, Montialoux H, Moreno C, Conti F, Silvain C, Perré P, Habersetzer F, Abergel A, Debette-Gratien M, Dharancy S, Esnault VLM, Fougerou-Leurent C, Cagnot C, Diallo A, Veislinger A, Danjou H, Samuel D, Pageaux GP, Duclos-Vallée JC,
Aliment. Pharmacol. Ther.. 2018 Apr 17;:
12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation.
Houssel-Debry P, Coilly A, Fougerou-Leurent C, Jezequel C, Duvoux C, De Ledinghen V, Radenne S, Kamar N, Leroy V, Di Martino V, D'Alteroche L, Canva V, Conti F, Dumortier J, Montialoux H, Lebray P, Botta-Fridlund D, Tran A, Moreno C, Silvain C, Besch C, Perre P, Francoz C, Abergel A, Habersetzer F, Debette-Gratien M, Cagnot C, Diallo A, Chevaliez S, Rossignol E, Veislinger A, Duclos-Vallee JC, Pageaux GP,
Hepatology. 2018 Apr 10;:
Direct acting antiviral agents-based regimen for HCV recurrence after combined liver-kidney transplantation: results from the ANRS CO23 CUPILT study.
Dharancy S, Coilly A, Fougerou-Leurent C, Duvoux C, Kamar N, Leroy V, Tran A, Houssel-Debry P, Canva V, Moreno C, Conti F, Dumortier J, Di Martino V, Radenne S, De Ledinghen V, D'Alteroche L, Silvain C, Besch C, Perré P, Botta-Fridlund D, Francoz C, Habersetzer F, Montialoux H, Abergel A, Debette-Gratien M, Rohel A, Rossignol E, Samuel D, Duclos-Vallée JC, Pageaux GP,
Am. J. Transplant.. 2017 Sep;:
Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study.
Mangia A, Foster GR, Berg CP, Curescu M, Ledinghen V, Habersetzer F, Manolakopoulos S, Negri E, Papatheodoridis G, Ahlers S, Castillo M, Bakalos G, Mauss S,
Ann Gastroenterol. 2017 ;30(3):327-343
Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
Pol S, Bourliere M, Lucier S, Hezode C, Dorival C, Larrey D, Bronowicki JP, Ledinghen VD, Zoulim F, Tran A, Metivier S, Zarski JP, Samuel D, Guyader D, Marcellin P, Minello A, Alric L, Thabut D, Chazouilleres O, Riachi G, Bourcier V, Mathurin P, Loustaud-Ratti V, D'Alteroche L, Fouchard-Hubert I, Habersetzer F, Causse X, Geist C, Rosa I, Gournay J, Saillard E, Billaud E, Petrov-Sanchez V, Diallo A, Fontaine H, Carrat F,
J. Hepatol.. 2017 Jan;66(1):39-47
Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin.
Tawar RG, Heydmann L, Bach C, Schüttrumpf J, Chavan S, King BJ, McClure CP, Ball JK, Pessaux P, Habersetzer F, Bartenschlager R, Zeisel MB, Baumert TF
Hepatology. 2016 Nov;64(5):1495-1506
Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study.
Coilly A, Fougerou-Leurent C, de Ledinghen V, Houssel-Debry P, Duvoux C, Di Martino V, Radenne S, Kamar N, D'Alteroche L, Leroy V, Canva V, Lebray P, Moreno C, Dumortier J, Silvain C, Besch C, Perre P, Botta-Fridlund D, Anty R, Francoz C, Abergel A, Debette-Gratien M, Conti F, Habersetzer F, Rohel A, Rossignol E, Danjou H, Roque-Afonso AM, Samuel D, Duclos-Vallée JC, Pageaux GP,
J. Hepatol.. 2016 Oct;65(4):711-8
Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure.
Dumortier J, Bailly F, Pageaux GP, Vallet-Pichard A, Radenne S, Habersetzer F, Gagnieu MC, Grangé JD, Minello A, Guillaud O, Kamar N, Alric L, Leroy V
Nephrol. Dial. Transplant.. 2016 Oct;:
Usefulness of corticosteroids as first-line therapy in patients with acute severe autoimmune hepatitis.
Moenne-Loccoz R, Severac F, Baumert TF, Habersetzer F
J. Hepatol.. 2016 Aug;65(2):444-6
Management of large hepatocellular carcinoma by sequential transarterial chemoembolization and portal vein embolization: a systematic review of the literature.
Piardi T, Memeo R, Renard Y, Ammendola M, Bruno O, Habersetzer F, Baumert T, Pessaux P, Sommacale D
Minerva Chir. 2016 Jun;71(3):192-200
Acute hepatitis C virus infection induces anti-host cell receptor antibodies with virus-neutralizing properties.
Tawar RG, Colpitts CC, Timm J, Fehm T, Roggendorf M, Meisel H, Meyer N, Habersetzer F, Cosset FL, Berg T, Zeisel MB, Baumert TF
Hepatology. 2015 Sep;62(3):726-36
Anti-pseudo-PCNA type 1 (anti-SG2NA) pattern: Track down Cancer, not SLE.
Guffroy A, Dima A, Nespola B, Poindron V, Sibilia J, Herbrecht R, De Seze J, Habersetzer F, Andres E, Quoix E, Ohlmann P, Cribier B, Langer B, Martin T, Pasquali JL, Goetz J, Korganow AS
Joint Bone Spine. 2015 Sep 30. pii: S1297-319X(15)00151-7
Apolipoprotein E Mediates Evasion From Hepatitis C Virus-Neutralizing Antibodies.
Fauvelle C, Felmlee DJ, Crouchet E, Lee J, Heydmann L, Lefevre M, Magri A, Hiet MS, Fofana I, Habersetzer F, Foung SK, Milne R, Patel AH, Vercauteren K, Meuleman P, Zeisel MB, Bartenschlager R, Schuster C, Baumert TF
Gastroenterology. 2015 Sep 25. pii: S0016-5085(15)01358-X
A targeted functional RNAi screen uncovers Glypican 5 as an entry factor for hepatitis B and D viruses.
Verrier ER, Colpitts CC, Bach C, Heydmann L, Weiss A, Renaud M, Durand SC, Habersetzer F, Durantel D, Abou-Jaoude G, Lopez Ledesma MM, Felmlee DJ, Soumillon M, Croonenborghs T, Pochet N, Nassal M, Schuster C, Brino L, Sureau C, Zeisel MB, Baumert TF
Hepatology. 2015 Jul 29
Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation.
Forns X, Charlton M, Denning J, McHutchison JG, Symonds WT, Brainard D, Brandt-Sarif T, Chang P, Kivett V, Castells L, Prieto M, Fontana RJ, Baumert TF, Coilly A, Londono MC, Habersetzer F
Hepatology. 2015 May;61(5):1485-94
Trans-thoracic minimally invasive liver resection guided by augmented reality.
Hallet J, Soler L, Diana M, Mutter D, Baumert TF, Habersetzer F, Marescaux J, Pessaux P
J Am Coll Surg. 2015 May;220(5):e55-60
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Bourliere M, Bronowicki JP, de Ledinghen V, Hezode C, Zoulim F, Mathurin P, Tran A, Larrey DG, Ratziu V, Alric L, Hyland RH, Jiang D, Doehle B, Pang PS, Symonds WT, Subramanian GM, McHutchison JG, Marcellin P, Habersetzer F, Guyader D, Grange JD, Loustaud-Ratti V, Serfaty L, Metivier S, Leroy V, Abergel A, Pol S
Lancet Infect Dis. 2015 Apr;15(4):397-404
Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C.
Xiao F, Fofana I, Thumann C, Mailly L, Alles R, Robinet E, Meyer N, Schaeffer M, Habersetzer F, Doffoel M, Leyssen P, Neyts J, Zeisel MB, Baumert TF
Gut. 2015 Mar;64(3):483-94
Loss of hepatitis B surface antigen in a real-life clinical cohort of patients with chronic hepatitis B virus infection.
Habersetzer F, Moenne-Loccoz R, Meyer N, Schvoerer E, Simo-Noumbissie P, Dritsas S, Baumert TF, Doffoël M
Liver Int.. 2015 Jan;35(1):130-9
Interferon gamma-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune response.
Lin JC, Habersetzer F, Rodriguez-Torres M, Afdhal N, Lawitz EJ, Paulson MS, Zhu Y, Subramanian GM, McHutchison JG, Sulkowski M, Wyles DL, Schooley RT
J Infect Dis. 2014 Dec 15;210(12):1881-5
In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions.
Mangia A, Banyai T, De Bartolomeo G, Gervain J, Habersetzer F, Mulkay JP, Ouzan D, Parruti G, Passariello N, Remy AJ, Rizzetto M, Shiffman ML, Tice AD, Schmitz M, Tatsch F, Rodriguez-Torres M
Liver Int. 2014 Aug;34(7):e217-28
All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naive patients with genotype 1 HCV infection.
Wyles DL, Rodriguez-Torres M, Lawitz E, Shiffman ML, Pol S, Herring RW, Massetto B, Kanwar B, Trenkle JD, Pang PS, Zhu Y, Mo H, Brainard DM, Subramanian GM, McHutchison JG, Habersetzer F, Sulkowski MS
Hepatology. 2014 Jul;60(1):56-64
Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection.
Di Bisceglie AM, Janczweska-Kazek E, Habersetzer F, Mazur W, Stanciu C, Carreno V, Tanasescu C, Flisiak R, Romero-Gomez M, Fich A, Bataille V, Toh ML, Hennequi M, Zerr P, Honnet G, Inchauspe G, Agathon D, Limacher JM, Wedemeyer H
Gastroenterology. 2014 Jul;147(1):119-131.e3
Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents.
Xiao F, Fofana I, Heydmann L, Barth H, Soulier E, Habersetzer F, Doffoel M, Bukh J, Patel AH, Zeisel MB, Baumert TF
PLoS Pathog. 2014 May 15;10(5):e1004128
SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHESYS study.
D'heygere F, George C, Habersetzer F, Tripathi D, Q Pan C, Giron JA, Schmitz M, Tatsch F
Ann Hepatol. 2014 Mar-Apr;13(2):303-4.
Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies.
Arama V, Leblebicioglu H, Simon K, Zarski JP, Niederau C, Habersetzer F, Vermehren J, Bludzin W, Jinga M, Ulusoy S, Klauck I, Morais E, Bjork S, Lescrauwaet B, Kamar D, Zeuzem S
Antivir Ther. 2014;19(3):245-57
Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells.
Ramakrishnaiah V, Thumann C, Fofana I, Habersetzer F, Pan Q, de Ruiter PE, Willemsen R, Demmers JA, Stalin Raj V, Jenster G, Kwekkeboom J, Tilanus HW, Haagmans BL, Baumert TF, van der Laan LJ
Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):13109-13
Cirrhotic cardiomyopathy and hepatopulmonary syndrome: prevalence and prognosis in a series of patients.
Enache I, Oswald-Mammosser M, Woehl-Jaegle ML, Habersetzer F, Di Marco P, Charloux A, Doutreleau S
Respir Med. 2013 Jul;107(7):1030-6
Synthetic anti-lipopolysaccharide peptides and hepatitis C virus infection.
Habersetzer F, Leboeuf C, Doffoel M, Zeisel MB, Baumert TF
Expert Opin Investig Drugs. 2013 Jul;22(7):853-62
Hepatitis C virus vaccines--progress and perspectives.
Fauvelle C, Lepiller Q, Felmlee DJ, Fofana I, Habersetzer F, Stoll-Keller F, Baumert TF, Fafi-Kremer S
Microb Pathog. 2013 May;58:66-72
Genotype 1 hepatitis C virus envelope features that determine antiviral response assessed through optimal covariance networks.
Murray JM, Moenne-Loccoz R, Velay A, Habersetzer F, Doffoel M, Gut JP, Fofana I, Zeisel MB, Stoll-Keller F, Baumert TF, Schvoerer E
PLoS One. 2013 Jun 20;8(6):e67254
Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B.
Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, Habersetzer F, Sievert W, Wong D, Lovegren M, Cohen D, Llamoso C
Gastroenterology. 2012 Sep;143(3):619-28.e1
Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies.
Fofana I, Fafi-Kremer S, Carolla P, Fauvelle C, Zahid MN, Turek M, Heydmann L, Cury K, Hayer J, Combet C, Cosset FL, Pietschmann T, Hiet MS, Bartenschlager R, Habersetzer F, Doffoel M, Keck ZY, Foung SK, Zeisel MB, Stoll-Keller F, Baumert TF
Gastroenterology. 2012 Jul;143(1):223-233.e9
Boceprevir and personalized medicine in hepatitis C virus infection.
Habersetzer F, Leboeuf C, Doffoel M, Baumert TF
Pharmgenomics Pers Med. 2012;5:125-37
A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C.
Habersetzer F, Honnet G, Bain C, Maynard-Muet M, Leroy V, Zarski JP, Feray C, Baumert TF, Bronowicki JP, Doffoel M, Trepo C, Agathon D, Toh ML, Baudin M, Bonnefoy JY, Limacher JM, Inchauspe G
Gastroenterology. 2011 Sep;141(3):890-899.e1-4
Evolutionary history of hepatitis C virus genotype 5a in France, a multicenter ANRS study.
Henquell C, Guglielmini J, Verbeeck J, Mahul A, Thibault V, Lebray P, Laperche S, Trimoulet P, Foucher J, Le Guillou-Guillemette H, Fouchard-Hubert I, Legrand-Abravanel F, Metivier S, Gaudy C, D'Alteroche L, Rosenberg AR, Podevin P, Plantier JC, Riachi G, Saoudin H, Coppere H, Andre E, Gournay J, Feray C, Vallet S, Nousbaum JB, Baazia Y, Roulot D, Alain S, Loustaud-Ratti V, Schvoerer E, Habersetzer F, Perez-Serra RJ, Gourari S, Mirand A, Odent-Malaure H, Garraud O, Izopett J, Bommelaer G, Peigue-Lafeuille H, van Ranst M, Abergel A, Bailly JL
Infect Genet Evol. 2011 Mar;11(2):496-503
[Assisted reproductive technique for an opiates dependant couple].
Weil M, Yu Tim Y, Reichert M, Trabelsi C, Lang JP, Ohl J, Partisani M, Habersetzer F
Gynecol Obstet Fertil. 2011 Feb;39(2):e37-9
Hepatitis C virus entry and glucocorticosteroids.
Fafi-Kremer S, Habersetzer F, Baumert TF
J Hepatol. 2010 Dec;53(6):1148-50
Virological workshop. Resistance to nucleostidic analogue and AgHB quantification.
Fontanges T, Habersetzer F, Zoulim F
Presse Med. 2010 Oct;39:27-8.
[Tropism of hepatitis C virus for leukocytes-- importance of the analysis of viral E1 and E2 envelope glycoprotein genes by sequencing]
Moenne-Loccoz R, Razafinjatovo C, Habersetzer F, Ananna A, Doffoel M, Wolf P, Gut JP, Baumert T, Stoll-Keller F, Schvoerer E
Pathol Biol (Paris). 2010 Apr;58(2):170-4
Adaptive Immunity to Hepatitis C Virus
Zeisel MB, Fafi-Kremer S, Robinet E, Habersetzer F, Baumert TF, Stoll-Keller F
Viruses-basel. 2009 Sep;1(2):276-97
GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection.
Habersetzer F, Baumert TF, Stoll-Keller F
Curr Opin Mol Ther. 2009 Aug;11(4):456-62.
Prognostic indices for Budd-Chiari syndrome: valid for clinical studies but insufficient for individual management.
Rautou PE, Moucari R, Escolano S, Cazals-Hatem D, Denie C, Chagneau-Derrode C, Charpignon C, Ledinghen V, Grenouillet-Delacre M, Habersetzer F, Nousbaum JB, Denninger MH, Valla DC, Plessier A
Am J Gastroenterol. 2009 May;104(5):1140-6
Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients.
Pastor R, Habersetzer F, Fafi-Kremer S, Doffoel M, Baumert TF, Gut JP, Stoll-Keller F, Schvoerer E
World J Gastroenterol. 2009 Feb 14;15(6):753-5.
[Neutralizing antibodies in hepatitis C virus infection]
Fafi-Kremer S, Zeisel MB, Schvoerer E, Soulier E, Habersetzer F, Wolf P, Doffoel M, Baumert TF, Stoll-Keller F
Gastroenterol Clin Biol. 2008 May;32(5 Pt 1):491-8
Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis.
Nousbaum JB, Cadranel JF, Nahon P, Khac EN, Moreau R, Thevenot T, Silvain C, Bureau C, Nouel O, Pilette C, Paupard T, Vanbiervliet G, Oberti F, Davion T, Jouannaud V, Roche B, Bernard PH, Beaulieu S, Danne O, Thabut D, Chagneau-Derrode C, de Ledinghen V, Mathurin P, Pauwels A, Bronowicki JP, Habersetzer F, Abergel A, Audigier JC, Sapey T, Grange JD, Tran A
Hepatology. 2007 May;45(5):1275-81.
